Epilepsy Research
Volume 83, Issue 1 , Pages 44-51 , January 2009

No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy

  • J.M. Lynch

      Affiliations

    • Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    • National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
    • These authors contributed equally to this work.
    • ,
  • S.K. Tate

      Affiliations

    • Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    • National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
    • These authors contributed equally to this work.
    • ,
  • P. Kinirons

      Affiliations

    • The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
    • ,
  • M.E. Weale

      Affiliations

    • Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, 103 Research Drive, Rm 4006 GSRB II, Box 3471 DUMC, Durham, NC 27710, USA
    • ,
  • G.L. Cavalleri

      Affiliations

    • The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
    • ,
  • C. Depondt

      Affiliations

    • Service de Neurologie, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium
    • ,
  • K. Murphy

      Affiliations

    • The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
    • ,
  • D. O’Rourke

      Affiliations

    • The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
    • ,
  • C.P. Doherty

      Affiliations

    • Department of Neurology, St. James’s Hospital, James Street, Dublin 8, Ireland
    • ,
  • K.V. Shianna

      Affiliations

    • Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, 103 Research Drive, Rm 4006 GSRB II, Box 3471 DUMC, Durham, NC 27710, USA
    • ,
  • N.W. Wood

      Affiliations

    • Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    • ,
  • J.W. Sander

      Affiliations

    • Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    • National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
    • SEIN – Epilepsy Institutes of the Netherlands Foundation, Achterweg 5, 2103 SW Heemstede, The Netherlands
    • ,
  • N. Delanty

      Affiliations

    • Department of Neurology, Beaumont Hospital, Dublin 9, Ireland
    • Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
    • ,
  • D.B. Goldstein

      Affiliations

    • Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, 103 Research Drive, Rm 4006 GSRB II, Box 3471 DUMC, Durham, NC 27710, USA
    • These authors jointly supervised this work.
    • Corresponding Author InformationCorresponding author at: Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Tel.: +44 20 3108 0112; fax: +44 20 3108 0115.
    • ,
  • S.M. Sisodiya

      Affiliations

    • Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    • National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
    • These authors jointly supervised this work.
    • Corresponding Author InformationCorresponding author at: Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Tel.: +44 20 3108 0112; fax: +44 20 3108 0115.

Received 9 May 2008 ,Revised 15 August 2008 ,Accepted 12 September 2008.

References 

  1. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia. 2000;41:1276–1283
  2. Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia. 2006;47:431–436
  3. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat. Genet. 2003;33(Suppl.):228–237
  4. Cavalleri GL, Weale ME, Shianna KV, Singh R, Lynch JM, Grinton B, et al. Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case–control study. Lancet Neurol. 2007;6:970–980
  5. Cereghino JJ, Biton V, bou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236–242
  6. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). PNAS. 1999;96:15268–15273
  7. Depondt C, Yuen AW, Bell GS, Mitchell T, Koepp MJ, Duncan JS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J. Neurol. Neurosurg. Psychiatry. 2006;77:101–103
  8. Ferraro TN, Dlugos DJ, Buono RJ. Challenges and opportunities in the application of pharmacogenetics to antiepileptic drug therapy. Pharmacogenomics. 2006;7:89–103
  9. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat. Rev. Genet. 2003;4:937–947
  10. Kinirons P, McCarthy M, Doherty CP, Delanty N. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure. 2006;15:387–392
  11. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies. Seizure. 2004;13:475–477
  12. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 2004;101:9861–9866
  13. Mehta CR, Patel NR. A Fortran Subroutine for Fisher Exact Test on Unordered Rxc Contingency-Tables. Acm Trans. Math. Software. 1986;12:154
  14. O’Brien E, Murphy J, Tyndall A, Atkins N, Mee F, McCarthy G, et al. Twenty-four-hour ambulatory blood pressure in men and women aged 17 to 80 years: the Allied Irish Bank Study. J. Hypertension. 1991;9:355–360
  15. Purcell S, Cherny S, Sham PC. Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics. 2003;19:149–150
  16. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia. 2000;41:1179–1186
  17. Weber S, Beran RG. A pilot study of compassionate use of Levetiracetam in patients with generalised epilepsy. J. Clin. Neurosci. 2004;11:728–731
  18. Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher’s approach. J. Evol. Biol. 2005;18:1368–1373

PII: S0920-1211(08)00259-3

doi: 10.1016/j.eplepsyres.2008.09.003

Epilepsy Research
Volume 83, Issue 1 , Pages 44-51 , January 2009

Article Tools